Cancer therapy, DM5167, a second-generation PARP1 selective inhibitor, has received approval for IND application for a phase 1 trial in Korea
May 2023
Parkinson’s Disease Therapy Selected for Grant
Awarded a grant from the Korea Drug Development Fund to bolster its research and development efforts targeting disease.
April 2023
DM5167 Introduced in AACR 2023
Digmbio has released a poster presentation titled DM5167: A Novel Selective PARP1 Inhibitor Significantly Reduces Triple Negative Breast Cancers during AACR 2023.
January 2022
A Cancer Drug Candidate In-Licensed
Acquired the rights to a cancer drug candidate, a PARP1 inhibitor, through in-licensing from Chung Nam Univ. and Kukje Pharma.
August 2021
DM5167 Patent Registered
The DM5167 patent for a pharmaceutical composition targeting PARP1-related diseases was registered in Korea in August 2021. It has been issued across 14 global regions.
April 2021
National Research Grant for Alzheimer’s Disease
DigmBio Alzheimer’s disease project received a grant from Korea Dementia Research Center sponsored by the Ministry of Science & ICT and the Ministry of Health & Welfare.
December 2020
New Facilities Opened
New Headquarters and lab opened in Pangyo Valley, Korea.
September 2020
Alzheimer’s Disease Research Started.
DigmBio has initiated a collaborative effort with Daegu Catholic University for their Alzheimer\'s disease program.
April 2020
DigmBio Incorporated
DigmBio was founded, deriving its corporate name from the concept of paradigm-shifting biotechnology.
